Investigational drug · Phase 2
Lu AG13909
Also called: Asedebart
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cushing's Disease, Congenital Adrenal Hyperplasia, Adrenal Hyperplasia, Congenital.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Lu AG13909"
First trial start
2022
Dec 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lu AG13909", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cushing's Disease
- Congenital Adrenal Hyperplasia
- Adrenal Hyperplasia, Congenital
Approved drugs for the same conditions: Cushing's syndrome · Rare and genetic disease · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Lu AG13909" as an intervention, largest first.
- An Extension Trial of Asedebart in Participants With Congenital Adrenal HyperplasiaNot yet recruiting
H. Lundbeck A/SIndustry
NCT07859293 · 45 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 31, 2031
Drug: Asedebart · For: Adrenal Hyperplasia, Congenital
H. Lundbeck A/SIndustry
NCT05669950 · 42 participants (planned) · Start Dec 19, 2022 · Primary completion Sep 30, 2026
Drug: Lu AG13909 · For: Congenital Adrenal Hyperplasia
Sites: Ann Arbor, Michigan; Copenhagen, Denmark; Angers, France · 17 sites in all
- A Trial of Lu AG13909 in Adult Participants With Cushing's DiseaseActive, not recruiting
H. Lundbeck A/SIndustry
NCT06471829 · 16 participants · Start Jun 19, 2024 · Primary completion Aug 10, 2027
Drug: Lu AG13909 · For: Cushing's Disease
Sites: Ann Arbor, Michigan; St Louis, Missouri; Bron, France · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The evolution of new approaches to the treatment of congenital adrenal hyperplasia.
Merke DP, Auchus RJ · Endocr Rev 2026
- Advances in pharmacological treatment for congenital adrenal hyperplasia.
Graves LE, Falhammar H · Curr Opin Pediatr 2026
- What is the need for adrenalectomy in patients with congenital adrenal hyperplasia in the era of CRF1/ACTH inhibitors?
Fedorova O, Falhammar H · Front Endocrinol (Lausanne) 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.